- Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
- Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
- Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
- Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
- Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
More ▼
Key statistics
On Friday, Kiromic Biopharma Inc (KRBP:QBB) closed at 3.20, -21.57% below its 52-week high of 4.08, set on Jul 12, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.20 |
---|---|
High | 3.22 |
Low | 3.20 |
Bid | -- |
Offer | -- |
Previous close | 3.22 |
Average volume | 3.02k |
---|---|
Shares outstanding | 1.29m |
Free float | 891.30k |
P/E (TTM) | -- |
Market cap | 4.12m USD |
EPS (TTM) | -29.21 USD |
Data delayed at least 15 minutes, as of May 31 2024 20:36 BST.
More ▼